Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy Authors: Zhifang Li, Shengheng Xu, Xuelian Jiang, Xue Yang, Shaoheng Cui, Yuchao Lu, Xiao Duan, Jinping Zheng Published: 2026 ABSTRACT AbstractBackgroundChlorambucil (CLB) is a clinically effective alkylating agent for hematologic malignancies; however, its therapeutic application is severely hampered by poor aqueous solubility, rapid hydrolytic degradation in physiological fluids, and dose-dependent systemic toxicity. Conventional nanocarriers offer partial solutions but are limited by low drug loading (<10%) and complex fabrication. Prodrug strategy constructed by covalent modification of anticancer drugs can overcome these limitations, enabling improved physicochemical properties and tumor-specific drug release.MethodsAn amphiphilic prodrug (CLB-THAM) was synthesized by conjugating CLB to tromethamine (THAM), a pharmacopeial excipient with GRAS status. The prodrug was formulated into nanomicelles via nanoprecipitation and characterized by DLS and TEM. Hydrolytic stability, in vitro cytotoxicity against A20 lymphoma cells, apoptosis induction, cellular uptake, and in vivo antitumor efficacy in a syngeneic mouse model were systematically evaluated.ResultsCLB-THAM spontaneously self-assembled into monodisperse nanomicelles (91.8 nm, PDI 0.103) with an unprecedented drug loading of 70.5%. Using A20 cells as experimental models, the cytotoxic effects of CLB-THAM nanomicelles were investigated at 0–100 μmol/L for 24 h. Notably, the cell viability of CLB-THAM nanomicelles to A20 cells was significantly lower compared with free CLB (45.6% vs. 74.5% at 100 μM), with correspondingly higher apoptosis induction (48.5% vs. 39.0% at 30 μg·mL−1). In vivo, the nanoformulation achieved superior tumor suppression in A20 tumor-bearing mice (final tumor volume 421 mm3 vs. 610 mm3 for free CLB and 1424 mm3 for saline), while maintaining excellent hemocompatibility (hemolysis <5%) and minimal systemic toxicity as evidenced by body weight stability and histopathological analysis.ConclusionThis carrier-minimized prodrug platform concurrently overcomes the solubility, stability, and toxicity bottlenecks of nitrogen mustard chemotherapy, offering a simple and translatable strategy for enhancing the clinical efficacy of chlorambucil.Keywords: chlorambucil, tromethamine, prodrug, nanomicelles, cancer therapy Introduction Cancer remains a preeminent global health challenge, with chemotherapy serving as a cornerstone of clinical management.1–4 Within this therapeutic landscape, chlorambucil (CLB)-a bifunctional nitrogen mustard alkylating agent—holds significant clinical relevance for treating chronic lymphocytic leukemia and lymphomas due to its oral bioavailability and cost-effectiveness.5,6 Despite its therapeutic utility, CLB suffers from three intrinsic limitations that impede optimal clinical performance: profoundly limited aqueous solubility (<0.1 mg/mL) restricting bioavailability, dose-dependent systemic toxicities such as myelosuppression arising from nonspecific biodistribution, and critically, hydrolytic instability.7–9 The N,N-bis(2-chloroethyl)amine moiety of CLB undergoes rapid degradation in physiological fluids, decomposing into inactive mono- and di-hydroxy derivatives via hydrolysis-prone aziridinium intermediates.10 As evidenced in mesoporous carrier studies, >90% of free CLB degrades within 4 hours in simulated intestinal fluid (pH 6.8), severely compromising sustained-release formulations essential for metronomic chemotherapy and leading to suboptimal therapeutic concentrations in tumors.11 Conventional nanocarrier strategies-including polymeric micelles,12–17 liposomes,18–23 and inorganic nanoparticles-have sought to mitigate these limitations.24–28 However, these systems suffer from low drug loading (typically <15%) and require complex multi‑step fabrication reliant on organic solvents, which limits their clinical translation.6,29–34 Moreover, most of these carriers are composed of non‑degradable or slowly degradable polymers, raising long‑term safety concerns. Notably, mesoporous poly(MA-DVB) microspheres demonstrated that confining CLB within hydrophobic/π-rich pores retards hydrolysis (<10% degradation over 36 h),11 but their non-degradable nature, micron-scale sizes (250–550 μm) unsuitable for systemic delivery, and moderate loading efficiency (~35%) necessitate alternative approaches. To overcome these limitations, we propose a prodrug‑based nanoplatform leveraging tromethamine (THAM)-a pharmacopeial excipient (acid-base regulator) with GRAS (Generally Recognized as Safe) status-as a multifunctional modifier. THAM confers integrated advantages through its unique molecular architecture: (i) its three hydrophilic hydroxymethyl groups enable spontaneous self‑assembly into nanomicelles without surfactants, achieving an ultra‑high drug loading of 70.5% while circumventing CLB’s hydrophobicity; (ii) its intrinsic buffering capacity (pKa 8.1) maintains local pH <7, suppressing base‑catalyzed aziridinium formation and thereby improving colloidal stability; (iii) its established safety profile in clinical formulations (eg, fosfomycin tromethamine) eliminates chronic carrier toxicity concerns. Importantly, the CLB-THAM conjugate itself retains the intact bis(2-chloroethyl)amine alkylating structure. Thus, it can form the aziridinium ion directly without requiring amide bond cleavage, meaning that the conjugate is intrinsically active as an alkylating agent. This design simplifies the mechanism of action and avoids the need for enzymatic or hydrolytic release of free CLB. In this work, we synthesize the amphiphilic prodrug CLB-THAM and characterize its self-assembly into monodisperse nanomicelles (see Scheme 1). The hydrophobic drug chlorambucil (CLB) is conjugated with tromethamine (THAM) to form an amphiphilic prodrug, which self-assembles into nanomicelles in aqueous solution. Upon intravenous administration, the nanomicelles accumulate in tumor tissue through the enhanced permeability and retention (EPR) effect and are internalized by cells. The internalized nanomicelles are subsequently disassembled, resulting in the release of the CLB-THAM prodrug, which induces apoptosis via DNA alkylation. We systematically evaluate: (i) improved colloidal stability via THAM-mediated pH buffering, (ii) superior cytotoxicity against A20 lymphoma cells, (iii) in vivo tumor suppression efficacy, and (iv) hemocompatibility. This strategy pioneers a carrier-minimized platform that concurrently overcomes solubility, stability, and toxicity bottlenecks in nitrogen mustard chemotherapy, providing a translatable paradigm for optimizing clinical efficacy and safety through rational molecular design. Schematic illustration of the fabrication and antitumor mechanism of chlorambucil-tromethamine (CLB-THAM) nanomicelles. Materials and Methods Materials and Instrumentations Chlorambucil (98%) and 1-hydroxybenzotriazole (HOBt, 99%) were obtained from Bide Pharmatech Co., Ltd. Tromethamine (99%) was sourced from Shanghai Xianding Biotechnology Co., Ltd. N,N-Dicyclohexylcarbodiimide (DCC, 99%) was procured from Shanghai Haohong Scientific Co., Ltd. All other organic solvents and consumables were supplied by Jinbaiao Bio-Company (Changzhi, China). RPMI 1640 medium and fetal bovine serum (FBS) were acquired from Beijing Solaibao Technology Co., Ltd. and Zhejiang Tianhang Biotechnology Co., Ltd., respectively. The following reagents were purchased from Beyotime Biotechnology: the fluorescent probe DID (1,1′-dioctadecyl-3,3,3′3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt), Hoechst staining kit, penicillin-streptomycin solution (100X), trypsin (0.25%), phosphate-buffered saline (PBS), Annexin V-FITC apoptosis detection kit, and cell counting kit-8 (CCK-8). Balb/c nude mice were supplied by SPF (Beijing) Biotechnology Co., Ltd. (Beijing, China). All animal procedures were approved by the Animal Ethics Committee of Changzhi Medical College (Approval No. DW2024006Y) and were conducted in accordance with the guidelines for the use of laboratory animals (License No. SCXK (Jing) 2024–0001). All commercial kits and reagents were used according to the manufacturers’ protocols. Chemical reagents were used as received without further purification. The A20 cell line used in this study was purchased from Wuhan Zishan Biotechnology Co., Ltd. (originally sourced from ATCC, TIB-208). The cell line was authenticated and qualified by the supplier, with complete quality inspection reports, ensuring no mycoplasma contamination, no cross-contamination, and good cell viability, which meets the requirements of experimental cell use. Details of the instruments used in this work, including their sources and models, are provided in Table S1. Methods Synthesis of CLB-THAM Prodrug The synthetic route of the chlorambucil prodrug is provided in the Supporting Information (Figure S1), and the detailed synthetic procedure is as follows: Chlorambucil (304 mg, 1.0 mmoL) and N,N′-dicyclohexylcarbodiimide (DCC, 206 mg, 1.0 mmoL) were dissolved in anhydrous N,N-dimethylformamide (DMF, 20 mL) and stirred for 3 h in an ice bath. Subsequently, tromethamine (121 mg, 1.0 mmol) and 1-hydroxybenzotriazole (HOBt, 135 mg, 1.0 mmol) were added to the reaction mixture, which was then stirred at 40°C for 24 h. After the reaction was complete, the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using a mixture of dichloromethane, methanol, and tetrahydrofuran (DCM/MeOH/THF, 10:1:1, v/v/v) as the eluent to afford the title compound as a white solid in 37.5% yield. Preparation of CLB-THAM Nanomielles A sample of the Chlorambucil-Tromethamine prodrug (5 mg) was first dissolved in dimethyl sulfoxide (DMSO, 100 μL) at room temperature. This solution was then slowly added dropwise to deionized water (10 mL) under continuous magnetic stirring. The resulting solution was transferred into a dialysis bag (molecular weight cutoff, MWCO = 1000 Da) and dialyzed against deionized water for 24 h. Determination of Drug Loading in CLB-THAM Prodrug The drug loading content of CLB in the CLB-THAM prodrug was determined using UV-Vis spectrophotometry. Firstly, a CLB reference standard solution (50 μg·mL−1) was prepared in methanol. Serial dilutions were then made by transferring 0.40, 0.50, 0.666, 0.80, and 1.00 mL of this solution into separate 5 mL volumetric flasks, each diluted to the mark with methanol to obtain final CLB concentrations of 4, 5, 6.66, 8, and 10 μg·mL−1, respectively. The absorbance of each standard solution was measured at 257 nm (the maximum absorption wavelength of CLB) using a UV-Vis spectrophotometer, with methanol as the blank. A calibration curve was constructed by plotting absorbance (A) against concentration (C, μg·mL−1), and the linear regression equation was calculated. The CLB-THAM test solution was prepared in methanol. Its absorbance was measured in triplicate at 257 nm, and the mean absorbance was substituted into the calibration curve equation to obtain the actual concentration of CLB, which was then converted into the mass (m). Meanwhile, the total mass of CLB-THAM (W) was calculated. The drug loading content (DL) was then calculated according to the following equation: DL (%) = (m/W) × 100%. Cytotoxicity, Flow Cytometry Experiments and Hemolysis Test The cytotoxicity of CLB-THAM nanomicelles against A20 cells was evaluated using a Cell Counting Kit-8 (CCK-8) assay. Briefly, A20 cells were seeded in 96-well plates at a density of 10,000 cells per well in 100 μL of culture medium and pre-cultured for 12 h. The cells were then treated with 100 μL of fresh medium containing serial concentrations of free CLB, free THAM, a physical mixture of CLB/THAM, or CLB-THAM nanomicelles (n=5 per concentration). The final CLB-equivalent concentrations in the cultures for the CLB-containing groups were 0, 5, 15, and 30 μg·mL−1. After 24 h of incubation, 20 μL of CCK-8 solution was added to each well. Following a further incubation period (as per kit instructions), the absorbance at 450 nm was measured using a microplate reader. Cell viability was calculated relative to untreated control cells. The hemocompatibility of CLB-THAM nanomicelles and their suitability for intravenous administration were evaluated by a hemolysis assay. The experiment included the following eight groups: (1) CLB solution at 200 μg·mL−1, (2) CLB solution at 100 μg·mL−1, (3) CLB solution at 50 μg·mL−1, (4) CLB-THAM nanomicelles at 200 μg·mL−1, (5) CLB-THAM nanomicelles at 100 μg·mL−1, (6) CLB-THAM nanomicelles at 50 μg·mL−1, (7) pure water (positive control), and (8) 0.9% NaCl solution (negative control). After anesthetizing the nude mice, fresh blood was obtained using the eye socket blood collection method, washed several times with sterile PBS solution, and centrifuged at 1500 rpm each time until the supernatant was colorless and clear. Blood cells were added to 8 separate 2 mL centrifuge tubes at 0.1 mL per tube, and 1.5 mL of a pre-prepared solution was added to each, mixed, and then incubated in a 37°C incubator for 30 minutes. Finally, centrifuge at 1500 rpm for 3 minutes, and observe the results against a light background for recording. After aspirating the supernatant, 100 μL was added to each well of a 96-well plate, and the absorbance was measured at 540 nm using a microplate reader. The induction of apoptosis by the formulations was quantified using an Annexin V-FITC/PI apoptosis detection kit. A20 cells were seeded in 6-well plates and allowed to adhere for 12 hours. The cells were then treated with various concentrations (CLB concentration: 10 μg·mL−1, 15 μg·mL−1, 30 μg·mL−1) of free CLB or CLB-THAM nanomicelles for 24 hours. After treatment, the cells were harvested, washed with cold PBS, and resuspended in 1X Binding Buffer. Subsequently, the cells were stained with Annexin V-FITC and propidium iodide (PI) according to the manufacturer’s protocol (Beyotime Biotechnology). The stained cells were analyzed by flow cytometry within 1 hour to distinguish viable (Annexin V−/PI−), early apoptotic (Annexin V⁺/PI−), late apoptotic (Annexin V⁺/PI⁺), and necrotic (Annexin V−/PI⁺) cell populations. Intracellular Distribution of CLB-THAM Nanomicelles The cellular uptake of CLB-THAM nanomicelles by A20 cells was investigated using confocal laser scanning microscopy (CLSM). To prepare the fluorescently labeled nanomicelles (DID@CLB-THAM), the CLB-THAM prodrug (2 mg) and a DID solution in DMSO (20 μL, 5 mg·mL−1) were first co-dissolved via sonication. This mixture was then slowly dripped into PBS (2 mL) under stirring to form a nanomicellar solution (1 mg·mL−1). The resulting solution was dialyzed (MWCO = 1000 Da) against PBS for 12 h to remove unencapsulated DID. For the control, free DID was prepared by adding a DID solution (10 μL of the same stock) to PBS (2 mL) followed by sonication. A20 cells were seeded into confocal dishes (5×104 cells·mL−1 of cell fluid) and cultured for 12 h under standard conditions (37°C, 5% CO2). The culture medium was then replaced with 1 mL of fresh medium containing either DID-labeled CLB-THAM nanomicelles or free DID, both diluted 5-fold with medium. The cells were incubated with these formulations for 2, 4, or 8 h. After incubation, the cells were washed with PBS (pH 7.4) and fixed for 10 min. Following fixation, the cells were washed three times with PBS, and the nuclei were stained with Hoechst solution for 10 min. After subsequent washing with PBS (three times), the intracellular distribution of the fluorescence was immediately observed by CLSM after mounting with an antifade solution. Tumor Inhibition in vivo In vivo antitumor efficacy study was conducted using a syngeneic mouse model. Briefly, nude mice were subcutaneously injected in the right hind flank with 100 μL of A20 cell suspension (1.5 × 108 cells/mL), corresponding to 1.5 × 107 cells per mouse, to establish tumors. When the tumor volume reached approximately 50 mm3, the tumor-bearing mice were randomly divided into three groups (n = 7): (1) normal saline (negative control), (2) free chlorambucil (CLB), and (3) CLB-THAM nanomicelles. Treatments were administered intravenously via the tail vein at a CLB-equivalent dose of 3.6 mg/kg every other day. Mouse body weight and tumor volume were measured regularly throughout the treatment period. For histopathological analysis at different time points, one mouse per group was sacrificed on days 3 and 8 (these mice were excluded from the final efficacy endpoint analysis). The remaining mice (n=5 per group) were used for continuous monitoring of body weight and tumor volume. Major organs (heart, liver, spleen, lung, kidney) and tumor tissues were harvested, fixed in 4% paraformaldehyde, and processed for histological analysis. All remaining mice were sacrificed on day 15, and their organs and tumors were collected. (Mice were euthanized by intraperitoneal injection of pentobarbital sodium at a dose of 150 mg/kg. Pentobarbital sodium was provided by the Basic Laboratory of Changzhi Medical College). Tissue sections were prepared, deparaffinized, and subjected to histological and immunofluorescence analyses. To assess tumor cell apoptosis, sections from the CLB-THAM nanomicelles group were co-stained with DAPI and a FITC-conjugated TUNEL reagent (or an appropriate marker for dead cells) and visualized using laser scanning confocal microscopy (LSCM). Additionally, all organ sections were stained with hematoxylin and eosin (H&E) to evaluate potential systemic toxicity. Statistical Analysis All data are presented as mean ± standard error of the mean (SEM). For comparisons between two groups, an independent samples Student’s t-test was used. For multiple comparisons among three or more groups, a one-way analysis of variance (ANOVA) followed by the Tukey’s post-hoc post-hoc test was applied. Statistical analysis was performed using GraphPad Prism 9.0 software. A two-tailed P-value < 0.05 was considered statistically significant. In all experiments, n represents the number of independent replicates. Specifically, for in vivo experiments, n = 5 mice per group. For in vitro experiments (including cytotoxicity and hemolysis assays), n = 5 independent wells per condition. All error bars represent the standard deviation (SD). Results and Discussion Synthesis and Characterization The chemical structure of the CLB-THAM prodrug was confirmed by 1H NMR, 13C NMR, and mass spectrometry (MS). The corresponding spectra are provided in the Supporting Information (Figures S2–S4). Determination of Drug Loading Content The calibration curve of CLB in methanol showed excellent linearity over the concentration range of 4–10 μg·mL−1. The linear regression equation was y = 0.0631x - 0.0086 (R2 = 0.9994), where y is the absorbance at 257 nm and x is the CLB concentration (μg·mL−1) (Figure S5). The CLB-THAM test solution was prepared in methanol at a nominal concentration of 10 μg·mL−1, and its absorbance was measured in triplicate at 257 nm, giving a mean absorbance of 0.436 (n = 3) (Figure S6). Substituting this value into the calibration curve equation yielded a measured CLB concentration of 7.05 μg·mL−1. The mass of CLB (m) was obtained by multiplying the measured concentration by the solution volume, and the total mass of CLB-THAM (W) was calculated from the nominal concentration. The drug loading content (DL) of CLB in the CLB-THAM prodrug was then calculated as DL (%) = (m/W) × 100% = 70.46%, which is consistent with the calculated value of 70.5%. Characterization of CLB-THAM Nanomicelles The self-assembly capability of the CLB-THAM prodrug into nanomicelles was investigated to construct a nanodrug delivery system. The formation and morphology of the assemblies were confirmed by transmission electron microscopy (TEM), while their hydrodynamic diameter and size distribution were determined by dynamic light scattering (DLS). The CLB-THAM prodrug was formulated into nanomicelles in aqueous solution via the nanoprecipitation method. The hydrodynamic diameter and size distribution of the resulting nanomicelles were first determined by DLS. As shown in Figure 1a, the CLB-THAM prodrug self-assembled into nanomicelles with an average diameter of approximately 91.8 nm and a narrow polydispersity index (PDI) of 0.103, indicating a relatively uniform size distribution. The nanomicelles exhibited good stability over five days (120 h) at 25°C, with no significant change in particle size observed. Furthermore, TEM was used to characterize the morphology of the assemblies. The TEM image (Figure 1b) revealed that the nanomicelles were nearly spherical in shape and of uniform small size, The average diameter observed by TEM was smaller than that measured by DLS, which is expected because DLS measures the hydrodynamic diameter of hydrated particles in solution, while TEM visualizes dehydrated particles under vacuum. Both methods confirmed the formation of uniform, spherical nanomicelles. Characterization of CLB-THAM nanomicelles. (a) Hydrodynamic diameter stability of the nanomicelles in water over time, determined by DLS. (b) Representative TEM image illustrating the spherical morphology of the nanomicelles. Inset: The number-based size distribution of the nanomicelles obtained from DLS. Scale bar: 200 nm. Cytotoxicity, Flow Cytometry Experiments and Hemolysis Test The cytotoxicity of free THAM, free CLB, a CLB/THAM physical mixture, and CLB-THAM nanomicelles against A20 cells was evaluated using a CCK-8 assay after 24 hours of incubation. As shown in Figure 2a, free THAM exhibited no significant cytotoxicity across the tested concentration range (0–100 μM), indicating its good biocompatibility. At an equivalent CLB concentration of 100 μM, the cell viability values for the CLB group, the CLB/THAM mixture group, and the CLB-THAM nanomicelles group were 74.5%, 69.7%, and 45.6%, respectively (Figure 2a). These results demonstrate that the CLB-THAM nanomicelles elicited significantly enhanced cytotoxicity compared to an equivalent dose of free CLB or the physical mixture, highlighting the therapeutic advantage of the nano-formulation. In vitro antitumor efficacy and hemocompatibility evaluation. (a) Cytotoxicity of free THAM, free CLB, a CLB/THAM physical mixture, and CLB-THAM nanomicelles against A20 cells after 24 h of incubation, as determined by the CCK-8 assay. Data are presented as mean ± standard deviation (SD), (n = 5), *** means P < 0.001. (b) Photograph of the hemolysis assay after co-incubation of erythrocytes with different formulations. And Hemolysis rates of the CLB-THAM nanomicelles at different concentrations. Pure water and 0.9% NaCl solution were used as positive and negative controls, respectively. Data are presented as mean ± standard deviation (SD), (n = 5), *** means P < 0.001. Hemocompatibility is a critical prerequisite for the clinical translation of nanomedicines. A hemolysis assay was conducted to evaluate the safety of the formulations for intravenous administration by assessing their potential to damage erythrocyte membranes. The hemolytic activity was quantified by measuring the absorbance of the supernatant at 540 nm after co-incubation of the samples with erythrocytes. As shown in Figure 2b, the hemolysis rates of CLB-THAM nanomicelles at concentrations of 200, 100, and 50 μg·mL−1 were all below 5%, which is a widely accepted threshold for hemocompatibility. These results indicate that the nanomicelles did not induce significant hemolysis and possess favorable biosafety, supporting their potential for intravenous administration. The pro-apoptotic effect of the formulations was further quantified by flow cytometry using Annexin V-FITC/PI staining. As shown in Figure 3, at an equivalent CLB concentration of 30 μg·mL−1, the apoptosis rate induced by CLB-THAM nanomicelles was significantly higher than that induced by the parent drug CLB (48.5% vs. 39.0%). This result unequivocally demonstrates that the prodrug-based nanodelivery strategy significantly enhances the ability of chlorambucil to trigger programmed cell death in A20 cells, thereby contributing to its superior cytotoxicity. Flow cytometric analysis of apoptosis in A20 cells induced by free CLB and CLB-THAM nanomicelles. Cells were treated with various concentrations (5, 15, and 30 μg·mL−1, CLB-equivalent) for 24 h, and apoptosis was assessed by Annexin V-FITC/PI staining. Intracellular Distribution of CLB-THAM Nanomicelles To track the cellular distribution of CLB-THAM nanomicelles, DID-labeled nanomicelles (DID@CLB-THAM) were prepared and incubated with A20 cells. As shown in the merged fluorescence images in Figure 4, blue indicates Hoechst-stained nuclei, and red represents the DID signal. At 2 h of incubation, free DID molecules were already visible in the cytoplasm, while DID@CLB-THAM nanomicelles had not yet accumulated appreciably in the cells. By 4 h, both the nanomicelles and free DID had localized around the nucleus. After 8 h, the DID@CLB-THAM nanomicelles had efficiently entered the nucleus, whereas a portion of free DID remained excluded from the nuclear compartment. This distinct distribution pattern suggests that the nanomicelles were internalized primarily via endocytosis, a pathway that may help circumvent efflux pumps and facilitate intracellular drug retention, leading to the observed enhanced nuclear accumulation compared to free dye. Comparative analysis of the cellular uptake and localization of free DID and DID@CLB-THAM nanomicelles in A20 cells over time. CLSM images after 2 h, 4 h, and 8 h of incubation reveal differences in uptake pathways and distribution patterns between the two formulations. Scale bar: 50 μm. Tumor Inhibition in Vivo In vivo antitumor efficacy was further evaluated in a murine syngeneic model. The results demonstrated that CLB-THAM nanomicelles exhibited significantly enhanced therapeutic efficacy compared to free CLB. Body weight changes were monitored as an indicator of systemic toxicity throughout the study period. As shown in Figure 5a, mice treated with CLB-THAM nanomicelles maintained stable body weight without significant reduction, indicating the favorable biosafety profile of the nanoformulation. Tumor growth inhibition was quantitatively assessed by measuring tumor volume and weight. The final average tumor volumes were 1424 mm3 for the saline group, 610 mm3 for the free CLB group, and 421 mm3 for the CLB-THAM nanomicelles group (Figure 5b). Consistent with these findings, the average tumor weights followed the same trend, measuring 1.90 g, 0.92 g, and 0.53 g for the respective groups (Figure 5c). Visual examination of excised tumors provided further evidence of the superior antitumor effect of the nanomicelles, showing remarkable reduction in tumor size compared to both control groups (Figure 5d). These results collectively demonstrate the outstanding in vivo antitumor efficacy of the CLB-THAM nanomicellar formulation. In vivo antitumor efficacy and safety evaluation of CLB-THAM nanomicelles in A20 tumor-bearing mice. (a) Body weight changes of mice during the 15-day treatment period, Data are presented as mean ± standard deviation (SD), (n = 5), *** means P < 0.001. (b) Tumor growth curves showing tumor volume as a function of time after administration of saline, free CLB, or CLB-THAM nanomicelles, Data are presented as mean ± standard deviation (SD), (n = 5), * means P < 0.05, *** means P < 0.001. (c) Final tumor weights measured on day 15, Data are presented as mean ± standard deviation (SD), n = 5, *** means P < 0.001. (d) Representative photographs of excised tumors from each treatment group at the end of the experiment. (e) Histopathological analysis of major organs (heart, liver, spleen, lung, kidney) and tumor tissues by H&E staining. Scale bar: 50 μm. (f) Apoptosis in tumor tissues detected by TUNEL staining. Scale bar: 25 μm. Finally, after 15 days, all mice were euthanized, and major organs (heart, liver, spleen, lungs, and kidneys) along with tumor tissues were harvested for histopathological examination. Hematoxylin and eosin (H&E) staining on days 3, 8, and 15 (Figure S7) revealed no significant morphological damage or lesions in the major organs of mice treated with CLB-THAM nanomicelles, comparable to the saline control group. At the treatment endpoint (day 15), histological evaluation of tumor tissues showed marked differences among the groups (Figure 5e). The saline control group displayed large, intact nuclei characteristic of active proliferation. The free CLB group exhibited a noticeable reduction in nuclear density with signs of partial cellular injury. In contrast, the CLB-THAM micelle group showed extensive tissue destruction, accompanied by severe nuclear shrinkage and fragmentation. In contrast, TUNEL staining of tumor sections (Figure 5f) demonstrated extensive apoptosis in the nanomicelles group, significantly exceeding the levels observed in both the free CLB and saline control groups. These collective findings indicate that the CLB-THAM nanomicelles achieve potent antitumor efficacy while inducing minimal systemic toxicity, highlighting their high therapeutic index and potential as a safe and effective nanodrug delivery system. It should be noted that CLB-THAM itself possesses the intact bis(2-chloroethyl)amine alkylating structure. Even without amide bond cleavage, the 2-chloroethyl groups can undergo intramolecular cyclization to form the aziridinium ion under physiological conditions. Thus, the amide bond does not need to be hydrolyzed for the prodrug to exert its antitumor effect. The nanomicellar formulation primarily improves solubility and passive tumor targeting, while the alkylating function resides in the CLB-THAM molecule itself. Conclusion In this study, we successfully developed a carrier-minimized prodrug strategy by conjugating chlorambucil to tromethamine, a pharmacopeial excipient with intrinsic pH-buffering capacity. The resulting CLB-THAM prodrug spontaneously assembled into stable, monodisperse nanomicelles with a high drug loading of 70.5% and improved colloidal stability. The nanoformulation demonstrated superior in vitro cytotoxicity and in vivo antitumor efficacy compared to free CLB, while maintaining an excellent safety profile. By integrating the dual advantages of physical shielding and pH modulation, this THAM-based prodrug design concurrently addresses the critical solubility, stability, and toxicity limitations of nitrogen mustard agents. This work provides a simple and translatable platform for improving the therapeutic index of conventional chemotherapy, with potential applications extending beyond chlorambucil to other hydrophobic and hydrolysis-prone drugs. Acknowledgments This work was supported by the National Natural Science Foundation of China (grant No. 82204327), the Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province (No. 20230043), the program of Top Young Talented Scientist in Shanxi Province (No. SJYC2024211), the Shanxi Scholarship Council of China (No. 2024-136) and the Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi (No. 2024Q032), the Doctoral Research Foundation Project of Changzhi Medical College (No.2024BS04), the Fundamental Research Program of Shanxi Province (No. 202403021221212), the Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi (Grant 2024L278), the Research Foundation Project of Changzhi Medical College (Grant HZZD202406). Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors had no conflicts of interest in this work. References